Anti-angiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cells

Vascular Pharmacology

Volumn 52, Issue 1-2, 2010, Pages 46-54

  Zhu, Wenbo ^a   He, Songmin ^a   Li, Yan ^a   Qiu, Pengxin ^a   Shu, Minfeng ^a   Ou, Yanqiu ^a   Zhou, Yuehan ^a   Leng, Tiandong ^a   Xie, Jun ^a   Zheng, Xiaoke ^a   Xu, Dong ^a   Su, Xingwen ^a   Yan, Guangmei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Anaplastic thyroid carcinoma; NF B; Triptolide; Tumor angiogenesis; Vascular endothelial cells; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRIPTOLIDE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; DITERPENE; EPOXIDE; PHENANTHRENE DERIVATIVE;

ANAPLASTIC CARCINOMA; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; TUMOR CELL; TUMOR GROWTH; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; CARCINOMA; CELL CULTURE; CELL MOTION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; THYROID NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL MOVEMENT; CELLS, CULTURED; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; EPOXY COMPOUNDS; HUMANS; PHENANTHRENES; THYROID NEOPLASMS;

EID: 76049110182     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.10.006     Document Type: Article

References (37)

1. Abdollahi A., Lipson K.E., Sckell A., Zieher H., Klenke F., Poerschke D., Roth A., Han X., Krix M., Bischof M., Hahnfeldt P., Grone H.J., Debus J., Hlatky L., and Huber P.E. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res. 63 (2003) 8890-8898
2. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 6 (2004) 203-208
3. Ain K.B. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8 (1998) 715-726
4. Bikfalvi A., and Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol. Sci. 23 (2002) 576-582
5. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
6. Carter B.Z., Mak D.H., Schober W.D., McQueen T., Harris D., Estrov Z., Evans R.L., and Andreeff M. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 108 (2006) 630-637
7. Coultas L., Chawengsaksophak K., and Rossant J. Endothelial cells and VEGF in vascular development. Nature 438 (2005) 937-945
8. Dhanabal M., Ramchandran R., Waterman M.J., Lu H., Knebelmann B., Segal M., and Sukhatme V.P. Endostatin induces endothelial cell apoptosis. J. Biol. Chem. 274 (1999) 11721-11726
9. Fang J., Zhou Q., Liu L.Z., Xia C., Hu X., Shi X., and Jiang B.H. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 28 (2007) 858-864
10. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
11. Folkman J., Hahnfeldt P., and Hlatky L. Cancer: looking outside the genome. Nat. Rev. Mol. Cell. Biol. 1 (2000) 76-79
12. Goto H., Yano S., Zhang H., Matsumori Y., Ogawa H., Blakey D.C., and Sone S. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res. 62 (2002) 3711-3715
13. Gu W.Z., Chen R., Brandwein S., McAlpine J., and Burres N. Isolation, purification, and characterization of immunosuppressive compounds from tripterygium: triptolide and tripdiolide. Int. J. Immunopharmacol. 17 (1995) 351-356
14. Hanford H.A., Wong C.A., Kassan H., Cundiff D.L., Chandel N., Underwood S., Mitchell C.A., and Soff G.A. Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells. Cancer Res. 63 (2003) 4275-4280
15. He M.F., Huang Y.H., Wu L.W., Ge W., Shaw P.C., and But P.P. Triptolide functions as a potent angiogenesis inhibitor. Int. J. Cancer 126 (2010) 266-278
16. Heroult M., Bernard-Pierrot I., Delbe J., Hamma-Kourbali Y., Katsoris P., Barritault D., Papadimitriou E., Plouet J., and Courty J. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Oncogene 23 (2004) 1745-1753
17. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23 (2005) 1011-1027
18. Hoffmann S., Rockenstein A., Ramaswamy A., Celik I., Wunderlich A., Lingelbach S., Hofbauer L.C., and Zielke A. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Mol. Cell. Endocrinol. 264 (2007) 74-81
19. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., and Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 (1999) 1994-1998
20. Huang S., Pettaway C.A., Uehara H., Bucana C.D., and Fidler I.J. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20 (2001) 4188-4197
21. Huang S., Robinson J.B., Deguzman A., Bucana C.D., and Fidler I.J. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 60 (2000) 5334-5339
22. Jain R.K., Duda D.G., Clark J.W., and Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3 (2006) 24-40
23. Jiang X.H., Wong B.C., Lin M.C., Zhu G.H., Kung H.F., Jiang S.H., Yang D., and Lam S.K. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene 20 (2001) 8009-8018
24. Kim S., Yazici Y.D., Calzada G., Wang Z.Y., Younes M.N., Jasser S.A., El-Naggar A.K., and Myers J.N. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol. Cancer Ther. 6 (2007) 1785-1792
25. Kong D., Li Y., Wang Z., Banerjee S., and Sarkar F.H. Inhibition of angiogenesis and invasion by 3, 3′-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res. 67 (2007) 3310-3319
26. Lee K.Y., Chang W., Qiu D., Kao P.N., and Rosen G.D. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J. Biol. Chem. 274 (1999) 13451-13455
27. Liu Q., Chen T., Chen G., Shu X., Sun A., Ma P., Lu L., and Cao X. Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NF-kappaB pathways. Mol. Immunol. 44 (2007) 2686-2696
28. Luboshitzky R., and Dharan M. Angiogenesis in thyroid cancers. Thyroid 14 (2004) 793-794
29. Mitchell J.C., and Parangi S. Angiogenesis in benign and malignant thyroid disease. Thyroid 15 (2005) 494-510
30. Pasieka J.L. Anaplastic thyroid cancer. Curr. Opin. Oncol. 15 (2003) 78-83
31. Qi J.H., Ebrahem Q., Moore N., Murphy G., Claesson-Welsh L., Bond M., Baker A., and Anand-Apte B. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. 9 (2003) 407-415
32. Qiu D., Zhao G., Aoki Y., Shi L., Uyei A., Nazarian S., Ng J.C., and Kao P.N. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J. Biol. Chem. 274 (1999) 13443-13450
33. Ribatti D. The involvement of endothelial progenitor cells in tumor angiogenesis. J. Cell. Mol. Med. 8 (2004) 294-300
34. Schmitt M., Wilhelm O., Janicke F., Magdolen V., Reuning U., Ohi H., Moniwa N., Kobayashi H., Weidle U., and Graeff H. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. J. Obstet. Gynaecol. 21 (1995) 151-165
35. Xu G., Pan J., Martin C., and Yeung S.C. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J. Clin. Endocrinol. Metab. 86 (2001) 1769-1777
36. Yang S., Chen J., Guo Z., Xu X.M., Wang L., Pei X.F., Yang J., Underhill C.B., and Zhang L. Triptolide inhibits the growth and metastasis of solid tumors. Mol. Cancer Ther. 2 (2003) 65-72
37. Zhu W., Ou Y., Li Y., Xiao R., Shu M., Zhou Y., Xie J., He S., Qiu P., and Yan G. A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappaB pathway. Mol. Pharmacol. 75 (2009) 812-819